-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- -- Following Positive Topline Data in RECONNECT Phase 2 Trial, Expect to Initiate Phase 3 Trial of RE104 in Postpartum Depression (PPD) in 2026 and RECLAIM Phase 2 Trial in Generalized Anxiety Disorder (GAD) in 1Q 2026-- MORRISTOWN, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatm ...